WALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3 Test and SilverStaff Clinical Laboratories, Inc. today announced that SilverStaff will be offering galectin-3 testing services to its laboratory customers and physicians.
The BGM Galectin-3 Test is a simple and affordable blood test that, when used in conjunction with clinical evaluation, is an aid in assessing the prognosis of patients with chronic heart failure by identifying those who are at greater risk of adverse events including hospitalizations and cardiovascular death . Having identified patients who are at higher risk of near-term adverse events, physicians and other health care providers may aim to better allocate scarce resources to those who need them the most [2,3].
"We are very pleased that SilverStaff will be offering galectin-3 testing services," said Paul R. Sohmer, M.D., President and CEO of BG Medicine. "We believe that growing interest in our test, as expressed by healthcare providers and regional clinical laboratories, reflects that our test has the potential to meet an unmet clinical need and the potential value associated with identifying chronic heart failure patients who are at higher risk of adverse events including hospitalizations, death and unnecessary readmissions."